ISPE to Outline Pharma's Future

This Sunday the 2012 ISPE Annual Meeting begins in San Francisco. The event will gather pharmaceutical professionals and regulatory authorities from around the world to discuss how the industry can continue to improve public health.

ISPE, the International Society for Pharmaceutical Engineering, boasts 20,000 members in scientific, technical, and regulatory positions. Founded in 1980, ISPE has its worldwide headquarters in Tampa, FL, and offices in Brussels, Belgium, Singapore, and Shanghai, China. 

"The pharmaceutical industry bears great responsibility for producing safe medicines that lengthen life expectancy and improve quality of life for patients around the world every day," said ISPE President and CEO Nancy Berg in a statement about the event. "The 20,000 pharmaceutical professionals who belong to ISPE dedicate their professional lives and countless hours of personal time working to improve development, production quality and distribution processes so that patients have life-saving medications that are reliably available and safe."

In the statement, ISPE pointed out the following achievements made by the pharmaceutical industry:

  • Medicines and treatments contributed to a 45% decline in deaths from heart attack and heart disease.
  • The survival rate for patients suffering from leukemia has quadrupled in the past 49 years, due to the development of new medications and the discovery of new uses for existing medications.
  • The rate of cancer deaths has dramatically declined, with one major study reporting that new medicines account for 50-60% of survival increases.
  • The survival rate of children with cancer has increased 40% since 1975.
  • Since the introduction of highly active antiretroviral treatments (HAART) in 1995, the death rate from AIDS has plummeted from 16.2 per 100,000 to just 2.7 in 2010.
  • Combination drug therapy can eliminate Hepatitis C in up to five out of 10 persons with the most common genotype in the U.S.
  • Multiple Sclerosis patients depend on numerous FDA-approved medications to improve their quality of life, and in some cases, slow the underlying course of the disease.


For more on ISPE's Annual Meeting, held November 11-14, visit www.ISPE.org/2012AnnualMeeting.

Visit www.ISPE.org for more information.

 

No votes yet